Iomed suffers setback for ophthalmic drug-delivery device
This article was originally published in Clinica
Executive Summary
Iomed's programme to develop a noninvasive ophthalmic drug delivery system for treating age-related macular degeneration has suffered a setback following the conclusion of feasibility, animal studies.